Figure 1.
Cumulative incidence of relapse in the groups treated with different immunosuppressive regimens. The h-ATG/CsA/sirolimus group (solid line) had a relapse rate of 28% by 3 years and the h-ATG/CsA taper group 25% (dotted line).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.